IMNM Q2 2024 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-44.5% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$40M-1692.4% margin

Net Income

-$36M-1528.0% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

+129.7%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$26M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$296M

Total Liabilities

$42M

Stockholders' Equity

$254M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-44.5%
Gross Profit	$2M	-$1M	+262.7%
Operating Income	-$40M	-$6M	-593.0%
Net Income	-$36M	-$6M	-550.0%